Deep optimized generation for antimicrobial peptide discovery

The DOG-AMP project aims to revolutionize antimicrobial peptide discovery using advanced deep optimized generation methods to combat antibiotic resistance effectively.

Subsidie
€ 1.998.471
2024

Projectdetails

Introduction

The DOG-AMP project will develop cutting-edge methods for Deep Optimized Generation (DOG) and use them to transform the emerging field of AntiMicrobial Peptide (AMP) discovery.

Background

Continuous overuse of antibiotics fuels the outgrowth and spread of multi-drug resistant microbial strains. Increasing antimicrobial resistance is already a major health and economic hazard, and is expected to account for 10 million deaths globally per year by 2050, exceeding deaths caused by cancer.

Importance of AMPs

AMPs are short peptides that can actively and selectively kill antibiotic-resistant pathogens, and as such are considered the most promising strategy for fighting antimicrobial resistance. Still, intensive research on AMP did not translate to their success in the clinic, mostly due to their lower activity and safety compared to existing antibiotics.

Objectives of the DOG-AMP Project

Deep optimized generation has the potential to radically advance AMP discovery, but only once unsolved problems are attacked and open research directions in this area are further explored to reach three major objectives of the DOG-AMP project:

  1. Develop a novel model, geared for deep optimized generation, combining the variational autoencoder framework with probabilistic modeling and algorithms for Pareto (conflicting multi-target) optimization, dealing with data scarcity and bias, generation diversity, and model interpretability.

  2. Combine the deep optimized generation model into a framework tailored for the specific needs of AMP design, e.g., accounting for AMP clustering, or conflicting features that make AMPs active or toxic.

  3. Apply the newly developed framework to explore and navigate the space of peptides to select and experimentally validate the best candidates that will supersede existing AMPs and antibiotics in their activity against hazardous microbes and safety.

Potential Impact

DOG-AMP has the potential to bring breakthroughs in the broad research areas of deep generative modeling, sequence optimization, and AMP discovery.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.998.471
Totale projectbegroting€ 1.998.471

Tijdlijn

Startdatum1-5-2024
Einddatum30-4-2029
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBHpenvoerder
  • UNIWERSYTET WARSZAWSKI

Land(en)

GermanyPoland

Vergelijkbare projecten binnen European Research Council

ERC Synergy ...

Deep learning analysis of imaging and metabolomic data to accelerate antibiotic discovery against antimicrobial resistance

AI4AMR aims to revolutionize antibiotic discovery by using advanced AI and multi-dimensional data analysis to identify novel antibiotics and their mechanisms of action against antimicrobial resistance.

€ 10.968.734
ERC Starting...

Scalable Microbial Metabolite Discovery Through Synthetic Biology

This project aims to enhance the discovery of microbial secondary metabolites by developing a scalable heterologous expression platform to access untapped biosynthetic genes for drug development.

€ 1.490.250
ERC Advanced...

Bacteriocins from interbacterial warfare as antibiotic alternative

BACtheWINNER aims to develop novel antimicrobials from bacteriocins through advanced bioengineering and molecular genetics to combat antimicrobial resistance and improve human and animal health.

€ 2.500.000
ERC Advanced...

Automated, miniaturized and accelerated drug discovery: AMADEUS

AMADEUS is an automated platform for rapid, sustainable drug discovery that synthesizes thousands of small molecules daily, optimizing processes through AI to reduce costs and enhance accessibility.

€ 3.409.401
ERC Advanced...

Harnessing Specialized Metabolism from Anaerobes

The AnoxyGen project aims to explore and harness the unique biosynthetic capabilities of anaerobic bacteria to discover novel metabolites and enhance biotechnological applications for health and ecology.

€ 2.499.859

Vergelijkbare projecten uit andere regelingen

EIC Pathfinder

Pharmaco-modulation of epithelia for induction of antimicrobial peptide expression: a disruptive approach to fight antibiotic resistance

MaxImmun aims to develop innovative molecules that enhance antimicrobial peptides to combat infections and antibiotic resistance, progressing towards clinical trials.

€ 3.194.450
EIC Pathfinder

Targeted Nano-formulations for Treatment of MRSA: A multicomponent platform for nano-formulated treatment of resistant microbial infections

LeadToTreat aims to develop targeted nano-formulations for treating MRSA infections by co-delivering novel low-drugability compounds and synergistic antibiotic combinations.

€ 2.665.564